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Abstract
Background: In pancreaticobiliary maljunction (PBM), the sphincter of Oddi can not control bile and pancreatic
juice flow, which may lead to two-way reflux of bile and pancreatic juice, thus causing chronic inflammation,
thickening, fibrosis and metaplasia of the common bile duct wall. These pathophysiological changes have been
linked to disruption of the epithelium barrier in the common bile duct. We hypothesized that the expression of
tight junction-associated proteins may be dysregulated in the common bile duct in PBM. In the current study, we
sought to analyze the expression of tight junction-associated proteins in the common bile duct epithelium of
pediatric patients with PBM.
Methods: Specimens of the common bile duct were collected from 12 pediatric patients with PBM and 10 non-PBM
controls. The expression of the tight junction-associated proteins occludin and claudin-1 in the epithelium was
examined by immunohistochemistry. The Image-Pro Plus v. 6.0 image analysis software was used to calculate the
mean qualifying score (MQS) of imunostained sections of common bile duct epithelium. Total protein extracts of
common bile duct were analyzed by Western blotting assays to examine expression of occludin, claudin-1 and myosin
light chain kinase (MLCK). Spearman correlation analysis was used to analyze the relation between MLCK and occludin,
MLCK and claudin-1.
Results: Immunostained sections of the common bile duct epithelium showed significantly higher MQS in pediatric
patients than controls for occludin (44.11 ± 13.82 vs. 11.30 ± 9.58, P = 0.0034) and claudin-1 (63.44 ± 23.59 vs.
46.10 ± 7.84, P = 0.0384). Western blotting also showed significantly higher expression of occludin, claudin-1
and MLCK in the common bile duct of patients than of controls (P = 0.0023, 0.0015, 0.0488). Spearman correlation
analysis showed that MLCK expression correlated positively with the expression of occludin (rs = 0.61538, P = 0.0032)
and claudin-1 (rs = 0.7972, P = 0.0019).
Conclusions: Occludin and claudin-1 are up-regulated in the common bile duct epithelium of pediatric PBM patients.
MLCK may be involved in the process of up-regulation of the tight junction-associated proteins in PBM.
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Background
Pediatric pancreaticobiliary maljunction (PBM) is a rare
congenital anomaly in which the main pancreatic and
bile ducts are joined outside the duodenal wall and form
a long common channel. The sphincter of Oddi in PBM
can not control bile and pancreatic juice flow, which
may lead to two-way reflux of bile and pancreatic juice
[1]. Pancreatic juice regurgitation causes mixing of the
pancreatic juice and bile, which activates multiple
pancreatins in the biliary duct, including phospholipase
A2 and trypsin, leading to chronic inflammation of the
biliary duct wall. Chronic inflammation of the biliary
duct eventually destroys the epithelial barrier and up-
regulates the expression of proliferating cell nuclear anti-
gen (PCNA), p53 and K-ras in biliary epithelial cells,
leading to malignant transformation [2–5].
Little is understood about how the epithelial barrier in
the common biliary duct is destroyed in patients with
PBM. A molecular understanding of this process may
help develop diagnostic markers for early detection of
PBM-related complications, including cancer, as well as
identify proteins and signaling pathways that may be
suitable targets for therapy.
Tight junctions are selectively permeable areas where
the membranes of neighboring cells lie in close appos-
ition, forming a virtually impermeable barrier to fluid
and maintaining cell polarity [6–8]. They are formed by
heterogeneous protein complexes containing numerous
proteins, including occludin, cingulin, symplekin, junc-
tional adhesion molecules, and members of the claudin
and zonula occludens (ZO) protein families [9, 10]. The
integrity of the epithelial barrier in the common biliary
duct depends on tight junctions between biliary duct
epithelial cells, which form an epithelial barrier that
prevents toxic substances, inflammatory factors and
pathogenic microorganisms from entering the bile duct
[11–16]. Occludin localizes specifically to tight junc-
tions, and its phosphorylation helps ensure correct
localization of functional junction complexes. Thus,
occludin is critical for maintaining intercellular perme-
ability and transepithelial resistance [6]. Each of the
various claudins in tight junctions has a particular ion
selectivity for ion transfer across the barrier [7, 8]. The
precise claudin composition in tight junctions varies
across tissues. For example, claudin-1 is important for
maintaining the gastrointestinal mucosal barrier [17].
Both occludin and claudin-1 play key roles in the biliary
epithelial barrier; in humans, and they localize primarily
to the bile duct and bile canaliculus [18].
It is possible that epithelial barrier disruption in PBM
involves tight junction dysregulation. Consistent with this
idea, experiments with a cell culture model system of
IgG4-related cholangitis point to dysfunction of the biliary
epithelial cell barrier [19]. In addition, experiments
showed that disruption of tight junction function and sub-
sequent leakage of the bile constituents may influence the
aggravation of cholestasis in primary biliary cirrhosis [20].
Fallon et al. reported that the levels of ZO-1 progres-
sively increased to 3-fold the levels in controls by 9 days
after induction of extrahepatic cholestasis; the levels of
occludin decreased within 2 days, which then gradually
recovered to the control levels by 9 days [11, 21].
Takakuwa et al. reported the mRNA transcript levels of
occludin increased in rat livers at 6 h after the common
bile duct was ligated [12]. These studies suggest that
disorders of the bile duct are associated with altered
expression of tight junction-associated proteins, raising
the possibility that the expression of tight junction-
associated proteins may be altered in PBM.
To examine whether PBM disrupts the epithelial cell
barrier and identify possible molecular pathways
involved, we measured the levels of several tight
junction-associated proteins in common bile duct tissue
specimens from pediatric patients with PBM. We
focused on occludin, claudin-1 and myosin light chain
kinase (MLCK), which have been shown to destroy
epithelial barrier function [22, 23]. The results lay the




The study protocol was approved by the Institutional
Ethics Review Committee at Children’s Hospital affili-
ated to Soochow University and the supervising local
health ministry. Informed consent was obtained from
the legal surrogates of the subjects following a detailed
description of the purpose of the study. All experiments
were carried out in strict accordance with the institution
guidelines regarding the acquisition and experimental
use of human tissues. Data were retrospectively analyzed
for all 12 pediatric patients (7 boys; median age, 3 years;
age range, 5 months – 8 years) diagnosed with PBM
who were admitted to our hospital between January
2011 and December 2014. In all patients, diagnosis was
confirmed by imaging and surgical pathological examin-
ation. PBM was diagnosed based on the following
criteria: (1) the union of pancreatic and biliary duct was
located outside the sphincter of Oddi, based on
magnetic resonance cholangiopancreatography (MRCP)
or intraoperative cholangiography (IOC); (2) the com-
mon duct was longer than 5 mm; (3) the biliary amylase
level was greater than 1000 U/L [24, 25]. Common bile
duct specimens were taken from PBM patients and
stored −20 °C until use.
As non-PBM controls, common bile duct specimens
were also collected from 10 deceased neonatal or
pediatric patients (6 boys; median age, 5 days; range, 1
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day to 8 years). The causes of death included neonatal
respiratory distress syndrome (n = 3), neonatal septi-
cemia (n = 2), neonatal pulmonary hemorrhage (n = 2),
intracranial hemorrhage (n = 2), and complex congenital
heart disease (n = 1). Pancreaticobiliary disease was ruled
out in all controls.
Immunohistochemistry
Paraffin-embedded specimens of the common bile duct
were serially sectioned (5 μm thick). Sections were
dewaxed and incubated in 3 % H2O2 at room temperature
for 30 min to inactivate endogenous peroxidase. After
rinse with distilled water and soak in phosphate-buffered
saline (PBS), antigen retrieval was done with citrate buffer
in a microwave oven, followed by blocking with 10 % goat
serum. Sections were then incubated with anti-occludin
antibody (1:300; Abcam, Cambridge, UK) and anti-
claudin-1 antibody (1:250; Abcam) at 4 °C overnight and
then at 37 °C for 45 min. Subsequently, the sections were
incubated with biotin-conjugated secondary antibody,
transferred to a 37 °C water bath for 20 min, incubated
with horseradish peroxidase (HRP)-conjugated streptavi-
din, placed in a 37 °C water bath for 20 min, and rinsed
with PBS four times (5 min each time). The sections were
visualized with DAB, re-stained with hematoxylin,
dehydrated, made transparent and enveloped. In par-
allel, positive controls (Abcam) were processed and
all gave positive staining; negative controls were
performed by replacing the primary antibody with
PBS, and all were negative for staining.
Sections containing epithelial tissue that stained posi-
tive for occludin and claudin-1 were observed under a
laser confocal scanning microscope (BX50 Olympus,
Japan) at a magnification of 400 ×. Immunohistochemi-
cal staining was quantitated using IPP 6.0 image analysis
software (Media Cybernetics, USA), and 5–8 fields of
view were selected on each section and photographed.
Image analyses were performed as described [26], and
qualifying scores (QS) were calculated using the follow-
ing formula: QS = percentage of positive cells × mean
intensity. Mean QS (MQS) were obtained for the various
fields of view in each section.
Western blotting assays
Common bile duct specimens were weighed, and 100-
mg samples were placed in 1 mL RIPA extraction buffer
and 10 μL phenylmethanesulfonyl fluoride (PMSF),
ground up, and centrifuged at 17,226 g for 30 min. The
supernatant was collected and stored at −20 °C until use.
Protein concentration was detected using the BCA
method (Pierce, USA). SDS-PAGE was performed using
a 5 % stacking gel and 15 % separation gel. Target pro-
tein bands were transferred to a nitrocellulose mem-
brane, blocked with non-specific antibody, incubated
overnight at 4 °C with anti-occludin antibody (1:250;
Abcam), anti-claudin-1 antibody (1:200; Abcam), and
anti-MLCK antibody (1:400; Abcam). After incubation
with HRP-conjugated secondary antibody, the protein
bands were visualized with enhanced chemilumines-
cence. Band intensities were quantified using digital
imaging analysis software (Tanon-1600, China).
Statistical analysis
All measurements were expressed as mean ± standard
deviation (SD). Differences in MQS (immunohistochem-
istry) or band intensities (Western blotting) between pa-
tients and controls were tested for statistical significance
using Student’s t test if they showed a normal distribution;
otherwise, they were tested using Wilcoxon test. Possible
correlation of MLCK band intensities with occludin or
claudin-1 band intensities was assessed using Spearman
rank correlation analysis. P < 0.05 was considered the
threshold of significance.
Results
Immunohistochemistry of tight junction-associated
proteins
The epithelial cells of the common bile duct appeared
columnar, and claudin-1 was expressed primarily on the
membrane of epithelial cells and less strongly in the
cytoplasm and nucleus (Fig. 1). The MQS for claudin-1
Fig. 1 Claudin-1 is expressed primarily on the membrane of epithelial cells and less strongly in the cytoplasm and nucleus (a: PBM, b: control)
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in the epithelial cells of the common bile duct were
63.44 ± 23.59 for PBM patients and 46.10 ± 7.84 for con-
trols (P = 0.0384).
Occludin was expressed at moderate levels on the
membrane of epithelial cells, and scantly in the cyto-
plasm and nucleus (Fig. 2). The MQS for occludin in the
epithelial cells of the common bile duct were 44.11 ±
13.82 for PBM patients and 11.30 ± 9.58 for controls
(P = 0.034; Table 1).
Western blotting of tight-junction associated proteins
Western blotting assays of total protein extracts from
common bile duct tissue showed significantly higher
levels of the three tight junction-associated proteins in
PBM patients than in controls (Table 2): claudin-1,
0.77 ± 0.54 vs. 0.20 ± 0.19 (P = 0.0023) (Fig. 3); occlu-
din, 0.67 ± 0.46 vs. 0.12 ± 0.10 (P = 0.0015) (Fig. 4) and
MLCK, 0.69 ± 0.58 vs. 0.25 ± 0.10 (P = 0.0488) (Fig. 5).
Spearman rank correlation analysis revealed that
MLCK expression correlated positively with the
expression of both occludin (r = 0.61538, P = 0.0032)
and claudin-1 (r = 0.7972, P = 0.0019) (Table 3).
Discussion
Here we showed that the expression of the tight
junction-associated proteins occludin and claudin-1 is
up-regulated in the epithelial cells of the common bile
duct of PBM patients, which provides the first molecular
clue that may help explain how this anatomical anomaly
leads to disruption of the epithelial barrier in the
common bile duct. We further demonstrated that the
expression of MLCK, which may be involved in the
disruption of the epithelial barrier in PBM, was up-
regulated in the epithelial cells of the common bile duct
of PBM patients.
In PBM, chronic contact between regurgitated pancre-
atic juice and the epithelial tissue of the common bile
duct leads to chronic inflammation, thickening, fibrosis
and metaplasia of the common bile duct wall [27]. The
fibrosis further causes uneven bile discharge as well as
elevated pressure and dilation within the common bile
duct [28]. These pathophysiological changes have been
linked to disruption of tight junctions in bile duct disor-
ders [29] and cholestasis, which shows similar pathology
to the cystic dilation of the common bile duct present in
all our patients. In a rat model of cholestasis, the severity
of changes in epithelial morphology and permeability in
the common bile duct correlated with impairment of
junctional integrity [30]. Ligating the common bile duct
in rats caused a redistribution of occludin [11, 21]; the
same procedure also up-regulated the mRNA transcript
levels of occludin without affecting the mRNA transcript
levels of claudin-1 or claudin-2 [12]. These findings
demonstrate that cholestasis affects the expression and
distribution of tight junction-associated proteins, which
may help explain our results in PBM. At the same time,
our observation that claudin-1 was up-regulated in the
Fig. 2 Occludin is expressed at moderate levels on the membrane of epithelial cells, and at very low levels in the cytoplasm and nucleus
(a: PBM, b: control)
Table 1 Immunohistochemical analysis of occludin and claudin-1
expression in the epithelial cells of the common bile duct of
pediatric patients with pancreaticobiliary maljunction (PBM) and
non-PBM controls
Group N Mean ± SDa P**
occludin PBM 12 44.11 ± 13.82 0.0034
Control 10 11.30 ± 9.58
claudin-1 PBM 12 63.44 ± 23.59 0.0384
Control 10 46.10 ± 7.84
aMean qualifying scores
**Wilcoxon two-sample test
Table 2 Expression of occludin, claudin-1 and myosin light chain
kinase (MLCK) in the common bile duct of pediatric patients with
PBM and non-PBM controls
Group N Mean ± SD P**
MLCK PBM 12 0.69 ± 0.58 0.0488
Control 10 0.25 ± 0.10
Occludin PBM 12 0.67 ± 0.46 0.0015
Control 10 0.12 ± 0.10
Claudin-1 PBM 12 0.77 ± 0.54 0.0023
Control 10 0.20 ± 0.19
**Wilcoxon two-sample test
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epithelial cells of the common bile duct of PBM patients
suggests that cholestasis alone may not explain all our
findings. The up-regulation of the tight junction-
associated proteins occluding and claudin-1 is mainly at-
tributable to the reflux of pancreatic juice into common
bile duct and cholestasis in PBM. This may represent an
adaptational response to preserve barrier function.
The up-regulation of occludin and claudin-1 in our
patients with PBM correlated with expression of MLCK,
and MLCK levels were significantly higher in patient tis-
sues than in control tissues. These results are consistent
with our previous work showing elevated MLCK expres-
sion in the common bile duct of patients with PBM [31].
This kinase helps to regulate the dynamic structure and
function of tight junctions, and it may be activated by
factors that damage the epithelial barrier [32, 33]. Our
findings prompt us to speculate that MLCK dysregula-
tion may be associated with impairment of the epithelial
barrier in the common bile duct in patients with PBM,
which, however, awaits further investigations.
Up-regulation of MLCK expression may compromise
the epithelial barrier via several possible mechanisms. It
may lead to increased myosin phosphorylation as alter-
ations of epithelial contraction have been shown to in-
crease mucosal permeability [33]. In intestinal epithelial
disorders caused by inflammation or endotoxin, alter-
ation of MLCK expression may alter the expression
levels of tight junction-associated proteins [22, 23, 34].
MLCK has already been implicated in processes that
damage the epithelial barrier in the bile duct, at least in
tight junction destruction induced by lipopolysaccharide
or H2O2: this damage is blocked by specific MLCK in-
hibitor ML-7 [35, 36]. Oxidative stress damage, which
has been shown to increase MLCK activity [37], is also
present in patients with PBM.
This study has several limitations. First, it was a retro-
spective and observational study, and therefore there
may have been some selection bias. Second, some of the
controls were from neonates. Neonatal tissues are
special and different from tissues of persons of older
ages, which may cause some selection bias. Third, the
sample size is small. Therefore, further animal experi-
ments and prospective studies are needed.
Conclusions
In summary, our data show that PBM in pediatric
patients is associated with up-regulation of the tight
junction-associated proteins occludin and claudin-1 in
Fig. 3 Representative Western blot of claudin-1 in the PBM group
versus the control group
Fig. 4 Representative Western blot of occludin in the PBM group
versus the control group
Fig. 5 Representative Western blot of MLCK in the PBM group versus
the control group
Table 3 Correlation between expression of MLCK protein and
expression of tight junction-associated proteins in the common
bile duct
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the common bile duct epithelium. Furthermore, the
expression of these two proteins with PBM correlated
with that of MLCK, which may be involved in the
process of up-regulation of the tight junction-
associated proteins in PBM. Our findings pave the
way for future studies to examine these alterations in
real time, in the presence of MLCK inhibitor ML-7
and while measuring transepithelial resistance. Such
work may help identify biomarkers for early detection
and diagnosis of PBM-related complications, as well
as elucidate pathological pathways that can be tar-
geted in drug development.
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